AG真人官方

Cytokinetics Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

SOUTH SAN FRANCISCO, Calif., July 18, 2025 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on July 16, 2025 it granted stock options to purchase an aggregate of 131,683 shares of common stock and 88,755 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting聽to 18 employees, whose employment commenced in June and July 2025 as a material inducement to their employment.

The RSUs will vest over 3 years, with 40% of the RSUs vesting on the first anniversary of the applicable grant date, an additional 40% of the RSUs vesting on the second anniversary of the grant date and the final 20% vesting on the third anniversary of the grant date, in each case, subject to each respective employee鈥檚 continued service with the Company. The stock options that were granted are subject to an exercise price of $38.68 per share, which is equal to the closing price of the Company鈥檚 common stock on July 16, 2025 and will vest over 4 years, with 1/4^th of the shares underlying the employee鈥檚 option vesting on the one-year anniversary of the grant date and the remaining shares thereafter vesting in monthly installments at a rate of 1/48th of the shares underlying such stock options over the subsequent 36 months, subject to each respective employee鈥檚 continued service with the Company. The stock options have a 10-year term. These awards are subject to the terms and conditions of the Company's Amended and Restated 2004 Equity Incentive Plan and the applicable award agreements pursuant to which the awards were granted.

The stock options and RSUs were granted as material inducements to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

About Cytokinetics

Cytokinetics聽is a specialty cardiovascular biopharmaceutical company, building on its over 25 years of pioneering scientific innovations in muscle biology, and advancing a pipeline of potential new medicines for patients suffering from diseases of cardiac muscle dysfunction.聽Cytokinetics聽is readying for potential regulatory approvals and commercialization of聽补蹿颈肠补尘迟别苍,听a cardiac myosin inhibitor, following positive results from SEQUOIA-HCM, the pivotal Phase 3 clinical trial in patients with obstructive hypertrophic cardiomyopathy (HCM).聽Aficamten聽is also being evaluated in additional clinical trials enrolling patients with obstructive and non-obstructive HCM.聽In addition,聽Cytokinetics聽is developing聽omecamtiv mecarbil, a cardiac myosin activator, in patients with heart failure with severely reduced ejection fraction (HFrEF), CK-586, a cardiac myosin inhibitor with a mechanism of action distinct from聽补蹿颈肠补尘迟别苍,听for the potential treatment of heart failure with preserved ejection fraction (HFpEF) and CK-089, a fast skeletal muscle troponin activator with potential therapeutic application to a specific type of muscular dystrophy and other conditions of impaired skeletal muscle function.

For additional information about Cytokinetics, visit 聽and follow us on , , and .

Forward-Looking Statements

This press release contains forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995 (the "Act").聽Cytokinetics聽disclaims any intent or obligation to update these forward-looking statements and claims the protection of the Act's聽Safe Harbor聽for forward-looking statements. Examples of such statements include, but are not limited to, statements relating to聽Cytokinetics'聽and its partners' research and development activities of Cytokinetics鈥� product candidates. Such statements are based on management's current expectations, but actual results may differ materially due to various risks and uncertainties, including, but not limited to the risks related to聽Cytokinetics'聽business outlined in聽Cytokinetics'聽filings with the聽Securities and Exchange Commission particularly under the caption 鈥淩isk Factors鈥� in Cytokinetics鈥� latest Annual Report on Form 10-K. Forward-looking statements are not guarantees of future performance, and聽Cytokinetics'聽actual results of operations, financial condition and liquidity, and the development of the industry in which it operates, may differ materially from the forward-looking statements contained in this press release. Any forward-looking statements that聽Cytokinetics聽makes in this press release speak only as of the date of this press release.聽Cytokinetics聽assumes no obligation to update its forward-looking statements whether as a result of new information, future events or otherwise, after the date of this press release.

CYTOKINETICS庐 and the CYTOKINETICS and C-shaped logo are registered trademarks of Cytokinetics in the U.S. and certain other countries.

Contact:
Cytokinetics
Diane Weiser
Senior Vice President, Corporate Affairs
(415) 290-7757